JPWO2023169360A5 - - Google Patents

Info

Publication number
JPWO2023169360A5
JPWO2023169360A5 JP2024553337A JP2024553337A JPWO2023169360A5 JP WO2023169360 A5 JPWO2023169360 A5 JP WO2023169360A5 JP 2024553337 A JP2024553337 A JP 2024553337A JP 2024553337 A JP2024553337 A JP 2024553337A JP WO2023169360 A5 JPWO2023169360 A5 JP WO2023169360A5
Authority
JP
Japan
Prior art keywords
caspase
seq
antibody
region
masked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509272A (ja
JP2025509272A5 (https=
Publication date
Priority claimed from PCT/CN2022/079475 external-priority patent/WO2023168547A1/en
Application filed filed Critical
Publication of JP2025509272A publication Critical patent/JP2025509272A/ja
Publication of JPWO2023169360A5 publication Critical patent/JPWO2023169360A5/ja
Publication of JP2025509272A5 publication Critical patent/JP2025509272A5/ja
Pending legal-status Critical Current

Links

JP2024553337A 2022-03-07 2023-03-06 抗cd137抗体ならびにその作製及び使用方法 Pending JP2025509272A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2022/079475 WO2023168547A1 (en) 2022-03-07 2022-03-07 Anti-cd137 antibodies and methods of making and using the same
CNPCT/CN2022/079475 2022-03-07
PCT/CN2023/079843 WO2023169360A1 (en) 2022-03-07 2023-03-06 Anti-cd137 antibodies and methods of making and using the same

Publications (3)

Publication Number Publication Date
JP2025509272A JP2025509272A (ja) 2025-04-11
JPWO2023169360A5 true JPWO2023169360A5 (https=) 2026-03-12
JP2025509272A5 JP2025509272A5 (https=) 2026-03-12

Family

ID=87936825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553337A Pending JP2025509272A (ja) 2022-03-07 2023-03-06 抗cd137抗体ならびにその作製及び使用方法

Country Status (10)

Country Link
US (1) US20250188179A1 (https=)
EP (1) EP4490204A1 (https=)
JP (1) JP2025509272A (https=)
KR (1) KR20240170602A (https=)
CN (1) CN119137159A (https=)
AU (1) AU2023229660A1 (https=)
CA (1) CA3244912A1 (https=)
MX (1) MX2024010847A (https=)
TW (1) TW202346352A (https=)
WO (2) WO2023168547A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019148445A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109651507B (zh) * 2017-10-12 2021-11-26 瑞阳(苏州)生物科技有限公司 一种激动型4-1bb单克隆抗体
WO2019148445A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
US11466086B2 (en) * 2019-10-11 2022-10-11 Nanjing Leads Biolabs Co., Ltd. Antibodies binding 4-1BB and uses thereof
CN112794905B (zh) * 2019-11-13 2022-10-04 合肥瀚科迈博生物技术有限公司 一种能够与人4-1bb结合的分子
CN117843786A (zh) * 2019-11-19 2024-04-09 非同(成都)生物科技有限公司 人源化4-1bb单克隆抗体及其药物组合物

Similar Documents

Publication Publication Date Title
US20220017640A1 (en) Activatable bispecific antibodies
KR101456326B1 (ko) 3가, 이중특이적 항체
CN102803295B (zh) 双特异性、四价抗原结合蛋白
US20170327579A1 (en) Bispecific antibodies against cd3epsilon and bcma
JP2021511808A5 (https=)
EP3204416A1 (en) Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
IL272349B2 (en) ANTI-CD137 antibodies
EP1299419A2 (en) Bispecific immunoglobulin-like antigen binding proteins and method of production
JPWO2019149281A5 (https=)
JPWO2020252264A5 (https=)
JP2015520168A (ja) 多重特異性抗体
RU2015101803A (ru) Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения
WO2010112194A1 (en) Antigen-binding polypeptides and multispecific antibodies comprising them
WO2019234241A1 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
JPWO2020229553A5 (https=)
US20250188172A1 (en) Compositions targeting epidermal growth factor receptor and methods for making and using the same
KR20250008811A (ko) 항-cd28 항체 및 이의 사용 방법
JP2026505405A (ja) 前立腺特異的膜抗原(psma)を標的とする組成物、並びにそれを作製及び使用するための方法
JPWO2023169360A5 (https=)
JPWO2021170068A5 (https=)
JPWO2023193817A5 (https=)
JPWO2023072177A5 (https=)
Gerspach Activatable bispecific antibodies The current invention relates to bispecific antibodies wherein the binding affinity to one of the two antigens is reduced and which can be activated by tumor-or inflammation-tissue/disease specific proteases (eg tumor-or inflammation-specific proteases); and the preparation and use of such bispecific antibodies.
NZ767462B2 (en) Anti-ctla4 antibodies and methods of making and using the same
KR20260011227A (ko) 마스킹된 항체, 라이브러리 및 이의 사용 방법